PSP Peripheral Immune Dysfunction
Overview
Peripheral immune dysfunction represents a critical yet underappreciated component of [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP) pathogenesis. While the central nervous system hallmarks of PSP (4R-tau aggregation, neuronal loss, neuroinflammation) are well-characterized, accumulating evidence demonstrates significant peripheral immune system alterations that may contribute to disease progression, provide diagnostic biomarkers, and offer therapeutic targets. The peripheral immune system communicates bidirectionally with the brain through multiple pathways—cellular trafficking, cytokine signaling, neural pathways, and glymphatic system modulation—making peripheral immune dysfunction a potentially modifiable target for intervention[@picillo2026][@massaro2024].
Peripheral Immune Cell Alterations
Natural Killer (NK) Cells
The NKscape Study (2026) represents a landmark investigation revealing significant natural killer (NK) cell alterations in PSP patients[@picillo2026]. This comprehensive characterization of NK cell populations identified several key findings:
- CD56bright NK cell reduction: Significant reduction in CD56bright NK cells in PSP patients compared to healthy controls and disease comparators
- Functional impairment: NK cells from PSP patients show reduced cytotoxic activity and interferon-gamma (IFN-γ) production capacity
- Phenotypic shifts: Altered expression of activating and inhibitory receptors including NKG2D, NKp46, and CD158b
- Disease correlation: NK cell alterations correlate with disease severity scores (PSPRS) and disease duration
- Potential link to peripheral immune surveillance disruption: Impaired NK cell function may allow persistence of pathological stimuli or dysregulated immune cell populations
The NK cell abnormalities in PSP suggest a broader dysregulation of innate immune surveillance. Given the role of NK cells in immune regulation and their ability to respond to cellular stress signals, these alterations may reflect or contribute to the pathological processes underlying PSP progression.
Monocyte and Macrophage Alterations
Peripheral monocytes in PSP show altered phenotypes and functions[@massaro2024][@bar2024]:
- CD14++CD16+ intermediate monocyte expansion: This pro-inflammatory monocyte subset is significantly increased in PSP patients
- Monocyte activation markers: Elevated expression of HLA-DR, CD86, and toll-like receptor 4 (TLR4) on monocytes from PSP patients
- Cytokine production: Increased production of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β upon stimulation
- Transmigration potential: Altered expression of matrix metalloproteinases (MMPs) may facilitate monocyte trafficking across the blood-brain barrier
- May contribute to neuroinflammation through peripheral-central immune interaction: Monocytes can migrate to the CNS and differentiate into macrophages, potentially propagating inflammatory signals
Transcriptional profiling of peripheral monocytes in 4R tauopathies (2025) revealed disease-specific gene expression signatures that distinguish PSP from CBS and other neurodegenerative conditions[@chen2025]. Key findings include upregulation of pro-inflammatory pathways (NF-κB signaling, IL-1β production) and downregulation of anti-inflammatory genes (IL-10, TGF-β). Single-cell RNA sequencing identified distinct monocyte subsets with altered frequencies in PSP, including a CD14+CD16+ intermediate population with high inflammatory gene expression.
The monocyte alterations in PSP appear distinct from other neurodegenerative conditions, potentially offering diagnostic discrimination from Parkinson's disease and Alzheimer's disease.
T Lymphocyte Abnormalities
T lymphocyte alterations provide insight into adaptive immune involvement in PSP[@hall2023]:
- CD8+ T cell changes: Altered CD8+ T cell populations with increased exhausted phenotypes (PD-1+, TIM-3+)
- CD4+ T cell shifts: Reduced regulatory T cell (Treg) numbers and function in PSP
- T cell cytokine profiles: Impaired T cell cytokine production capacity
- Autoimmune associations: Some studies report associations between PSP and autoimmune conditions
- Potential antigen-driven responses: Evidence for antigen-specific T cell responses to tau or neuronal antigens in some patients
TREM2 variants modulate peripheral immune responses in PSP, influencing monocyte and microglial function through the TREM2-DAP12 signaling axis[@patel2025]. Specific TREM2 polymorphisms associated with altered disease risk affect peripheral immune cell activation states, providing a mechanistic link between genetic risk factors and peripheral immune dysregulation.
The T cell abnormalities suggest that adaptive immune mechanisms may contribute to PSP pathogenesis, though the specific antigens driving these responses remain largely unidentified.
B Cell and Antibody Findings
B cell alterations and autoantibody findings in PSP include:
- Elevated B cell activating factor (BAFF): Increased BAFF levels in PSP patients may reflect ongoing B cell activation
- Autoantibody profiles: Some studies report increased autoantibodies against neuronal antigens in PSP
- Potential for antigen presentation: B cells may serve as antigen-presenting cells and influence T cell responses
- Therapeutic implications: B cell-targeted therapies have been proposed for PSP based on these findings
Cytokine and Chemokine Profiles
Pro-inflammatory Cytokines
Systemic inflammatory markers in PSP show characteristic patterns[@ruganzu2024][@pikkarainen2024]:
| Cytokine | Direction | Clinical Relevance |
|----------|-----------|-------------------|
| IL-6 | Elevated | Correlates with disease progression |
| TNF-α | Elevated | Associated with cognitive decline |
| IL-1β | Elevated/Variable | Links peripheral inflammation to CNS |
| IL-8 | Elevated | Associated with gait impairment |
| IFN-γ | Variable | May indicate immune activation |
CSF inflammatory marker profiling in PSP (2024) demonstrated elevated levels of IL-6, TNF-α, and CXCL10 compared to controls, with patterns distinct from AD and PD[@ruganzu2024]. The cytokine profile in PSP differs from Alzheimer's disease and Parkinson's disease, potentially providing diagnostic utility when combined with other biomarkers.
Chemokine Alterations
Chemokine alterations in PSP include[@kim2025]:
- CXCL10 (IP-10): Elevated in PSP plasma and CSF, associated with disease severity
- CCL2 (MCP-1): Variable levels; may facilitate monocyte recruitment
- CX3CL1 (Fractalkine): Altered; mediates neuron-microglial communication
- CCL11 (Eotaxin): Elevated in some PSP cohorts; associated with eosinophil recruitment
The CX3CL1-CX3CR1 axis dysfunction in PSP progression (2025) revealed that soluble CX3CL1 levels are altered in PSP patients, disrupting the protective neuron-microglia communication pathway[@kim2025]. CX3CR1-expressing monocytes and microglia show altered activation patterns when this signaling axis is disrupted, potentially contributing to increased neuroinflammation and tau pathology propagation.
Anti-inflammatory Cytokines
Counter-regulatory mechanisms include:
- IL-10: Often reduced in PSP, limiting anti-inflammatory compensation
- TGF-β: Variable; may be increased in some patients but functionally impaired
- IL-1RA: Elevated in some patients but insufficient to control inflammation
Blood-Brain Barrier Communication
Peripheral-Central Immune Pathways
Multiple pathways mediate communication between peripheral immune changes and CNS pathology in PSP:
Cellular trafficking: Monocytes and potentially T cells can cross the BBB and contribute to CNS inflammation
Cytokine signaling: Circulating cytokines can signal to brain endothelial cells and influence neuroinflammatory processes
Neural pathways: Vagus nerve innervation of peripheral immune organs provides direct neuro-immune communication
Glymphatic system: Peripheral immune activation may influence glymphatic clearance of toxic proteins
Soluble mediators: Exosomes and other extracellular vesicles carry inflammatory signals bidirectionallyBlood-Brain Barrier Permeability
Evidence for BBB alterations in PSP includes:
- Increased BBB permeability: Some studies report increased CSF/serum albumin ratio suggesting mild BBB disruption
- Endothelial dysfunction: Markers of endothelial activation (VCAM-1, ICAM-1) are elevated in PSP
- Pericyte involvement: Pericyte coverage may be reduced, compromising BBB integrity
- Transport alterations: Changed expression of drug transporters (P-gp) on BBB endothelial cells
Clinical Implications
Diagnostic Biomarker Potential
Peripheral immune markers offer potential for PSP diagnosis[@smith2025]:
- Multi-marker panels: Combination of NK cell markers, cytokines, and neuronal-derived extracellular vesicles improves diagnostic accuracy to 85-90%
- Disease discrimination: Peripheral immune profiles differ from PD, MSA, and CBS, potentially aiding differential diagnosis
- Disease stage markers: Some markers correlate with disease severity and progression rate
- Therapeutic monitoring: Immune markers may serve as pharmacodynamic biomarkers for immunomodulatory therapies
Neuron-derived extracellular vesicles (NDEVs) represent a particularly promising approach for detecting CNS pathology through peripheral blood sampling[@zheng2026]. Plasma NDEVs positive for tau species show promise as PSP-specific biomarkers, allowing indirect assessment of CNS tau pathology through peripheral blood analysis.
Disease Progression Markers
Longitudinal studies suggest:
- Baseline immune profiles predict progression: Elevated pro-inflammatory markers at baseline correlate with faster progression
- Longitudinal changes: Some immune markers show characteristic changes over disease course
- Survival associations: Certain immune parameters correlate with survival duration in PSP
Therapeutic Implications
Peripheral immune targets include:
- Anti-inflammatory approaches: Minocycline and other anti-inflammatory agents have been trialed in PSP
- Immunomodulation: Targeting specific immune pathways (IL-6, TNF-α) may modify disease progression
- Peripheral-central axis modulation: Therapies targeting peripheral immune activation may indirectly benefit CNS pathology
- Cellular therapies: NK cell and monocyte modulation strategies are under investigation
Comparison with Other Tauopathies
While both are 4R tauopathies, neuroimmune profiles differ between PSP and CBS[@constantinides2024]:
- NK cell alterations: More pronounced in PSP compared to CBS
- Cytokine patterns: Different cytokine elevation patterns between PSP and CBS
- Monocyte phenotypes: Distinct monocyte phenotypic shifts
- Autoimmune associations: Variable between conditions
Peripheral immune dysfunction in PSP shares some features with Alzheimer's disease but demonstrates distinct patterns that may reflect disease-specific pathophysiology.
Cross-Disease Comparison Table
| Immune Parameter | PSP | CBS | CBD | AD |
|-----------------|-----|-----|-----|-----|
| NK cell reduction | Marked | Moderate | Mild | Moderate |
| CD14++CD16+ monocytes | Elevated | Elevated | Variable | Elevated |
| IL-6 in CSF | High | Moderate | Moderate | High |
| Treg reduction | Yes | Yes | Variable | Yes |
| CXCL10 elevation | High | Moderate | Moderate | Variable |
Research Directions
Emerging Biomarkers
- Neuron-derived extracellular vesicles (NDEVs): Plasma NDEVs positive for tau species show promise as PSP-specific biomarkers[@zheng2026]
- Exosomal tau: Tau-containing exosomes in blood may reflect CNS pathology
- Multi-omics integration: Combining genomic, proteomic, and metabolomic data from blood samples
Therapeutic Targets
- Peripheral immune modulation: Strategies targeting peripheral immune activation
- Monocyte trafficking: Inhibiting monocyte migration to CNS
- Cytokine blockade: IL-6, TNF-α, and other cytokine-targeting approaches
- Cellular therapies: NK cell and Treg-based therapies
Future Research Priorities
Longitudinal peripheral immune profiling: Track immune changes across PSP disease stages
Single-cell resolution: Characterize immune cell subsets at single-cell level in larger cohorts
Mechanistic studies: Determine causality between peripheral immune changes and CNS pathology
Therapeutic trials: Test immunomodulatory strategies targeting peripheral immune dysfunctionSee Also
- [Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
- [Blood-Brain Barrier in PSP](/mechanisms/psp-blood-brain-barrier)
- [CSF and Blood Biomarkers in PSP](/biomarkers/psp-fluid-biomarkers)
- [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging)
- [TREM2 in Neurodegeneration](/mechanisms/trem2-microglial-activation)